Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/11/2018
SIETES contiene 92578 citas

 
 
 1 a 20 de 120 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Goldenberg JZ, Mertz D, Johnston BC. Probiotics to prevent Clostridium difficile Infection in patients receiving antibiotics. JAMA 2018;320:7 de agosto. [Ref.ID 102829]
3. Cita con resumen
Cook D, Guyatt G. Prophylaxis against upper gastrointestinal bleeding in hospitalized patients. N Engl J Med 2018;378:2506-16. [Ref.ID 102735]
5. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
6.Enlace a cita original Cita con resumen
Goldenberg JZ, Yap C, Lytvyn L, Ka-Fung Lo C, Beardsley J, Mertz D, Johnston BC. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database of Systematic Reviews 2018;12:19 de diciembre. [Ref.ID 102470]
8. Cita con resumen
Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med 2017;177:1308-15. [Ref.ID 102042]
9. Cita con resumen
Ma GK, Brensinger CM, Wu Q, Lewis JD. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study. Ann Intern Med 2017;167:152-8. [Ref.ID 101991]
10. Cita con resumen
Wei L, Ratnayake L, Phillips G, McGuigan CC, Morant SV, Flynn RW, Mackenzie IS, MacDonald TM. Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study. Br J Clin Pharmacol 2017;83:1298-308. [Ref.ID 101942]
11. Cita con resumen
Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of gastric acid suppression with recurrent Clostridium difficile infection: a systematic review and meta-analysis. JAMA Intern Med 2017;177:784-91. [Ref.ID 101618]
12.Enlace a cita original Cita con resumen
Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of gastric acid suppression with recurrent Clostridium difficile infection. A systematic review and meta-analysis. JAMA Intern Med 2017;177:784-91. [Ref.ID 101506]
13. Cita con resumen
Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim Y-S, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr M-B, for the MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 2017;376:305-17. [Ref.ID 101394]
14. Cita con resumen
Selvanderan SP, Summers MJ, Finnis ME, Plummer MP, Ali Abdelhamid Y, Anderson MB, Chapman MJ, Rayner CK, Deane AM. Pantoprazole or placebo for stress ulcer prophylaxis (POP-UP): randomized double-blind exploratory study. Crit Care Med 2016;44:1842-50. [Ref.ID 100852]
15. Cita con resumen
Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, Bakow B, Curran P, McKenney J, Tisch A, Reinert SE, Machan JT, Brandt LJ. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med 2016:23 de agosto. [Ref.ID 100599]
17.Enlace a cita originalTiene citas relacionadas Cita con resumen
Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med 2016;176:febrero. [Ref.ID 99958]
18. Cita con resumen
McDonald EG, Milligan J, Frenette C, Lee TD. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med 2015;175:784-91. [Ref.ID 99028]
19. Cita con resumen
20. Cita con resumen
Macy E, Contreras R. Adverse reactions associated with oral and parenteral use of cephalosporins: A retrospective population-based analysis. J Allergy Clin Immunol 2015;135:745-52. [Ref.ID 98852]
Seleccionar todas
 
 1 a 20 de 120 siguiente >>